NEW YORK and LONDON, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a previously announced securities purchase agreement for a private placement financing with a select group of institutional healthcare investors. With the closing of the transaction, Celsus will receive gross proceeds of approximately $12.5 million from the sale of 21,958,302 ordinary shares at a price of $0.57 per share.
Help employers find you! Check out all the jobs and post your resume.
